Introduction {#Sec1}
============

Hysterectomy is the most common gynecological operation and is widely accepted as the final treatment of many common gynecological diseases. However, the risk of reoperation increased due to complications of hysterectomy, such as pelvic adhesion. The recurrence of pelvic mass after hysterectomy is the common reason for reoperation \[[@CR1]--[@CR3]\]. It had been reported that simultaneous bilateral salpingectomy during hysterectomy may reduce the incidence of ovarian serous carcinoma and some benign pelvic diseases, thus reducing the risk of reoperation after hysterectomy \[[@CR4]--[@CR6]\]. Simultaneous bilateral salpingectomy has been routinely carried out in many medical institutions at present. However, few studies have explained whether salpingectomy affects the time of pelvic mass onset, clinical characteristics and pathological types of pelvic masses after hysterectomy in patients who have been treated again for various pelvic masses.

This study reviewed the medical records of patients received reoperation for pelvic masses following hysterectomy due to benign diseases, compared the clinical and pathological features in patients who underwent hysterectomy with or without bilateral salpingectomy, and analyzed the possible influence of simultaneous salpingectomy on the recurrence of pelvic masses.

Methods and materials {#Sec2}
=====================

Ethics {#Sec3}
------

This study was approved by the Ethics Committee of Peking Union Medical College Hospital (No. S-K331).

Patients {#Sec4}
--------

Identify patients who underwent surgery in Peking Union Medical College Hospital for pelvic mass after hysterectomy due to benign disease from January 2012 to December 2016 using ICD-9 disease code.

### Inclusion criteria {#Sec5}

A history of hysterectomy due to gynecological benign disease was clearly identified, and patients who underwent reoperation for pelvic mass during the required time period were included.

### Exclusion criteria {#Sec6}

Patients who underwent surgery for pelvic mass but had no history of hysterectomy, had a uterine pathology of malignant tumors, or whose surgery of pelvic mass was not performed in the specified period were excluded from the study.

Medical staff collected the medical records of enrolled patients in detail, including age of hysterectomy and the indications, age of the pelvic mass onset, time interval from the hysterectomy to the onset of pelvic mass, oviduct or ovary being resected or remained in previous surgery, main manifestations and imaging features at the time of pelvic mass onset, and pathological type of the pelvic mass. Patients were divided into two groups according to hysterectomy with or without bilateral salpingectomy, and the clinicopathological characteristics of two groups were compared and analyzed.

Statistics {#Sec7}
==========

The statistical analysis was performed using SPSS 23.0 (SPSS Inc., Chicago, IL, USA) in reference to whether the fallopian tubes were resected or not. Receiver Operating Characteristic (ROC) curve was constructed to define the optimal cutoff value for age of hysterectomy (\< 45 years vs ≥45 years), age of the operation for pelvic mass (\< 52 years vs ≥52 years), and time interval from the hysterectomy to the onset of pelvic mass (\< 5 years vs ≥5 years) (Table [1](#Tab1){ref-type="table"}, Fig. [1](#Fig1){ref-type="fig"}). Continuous variables were summarized with medians and interquartile ranges. Two groups were analyzed by independent t test, and multiple groups were analyzed by one-way ANOVA. The categorical variables were summarized with rates using Chi-square test or Fisher's exact test to analyze. Variables with *P* \< 0.05 by univariate analysis were included in multivariate analysis, and logistic regression model was used for fitting with *P* \< 0.05 considered statistical significance. All analysis was two-sided and significance level was set at *P* \< 0.05.Table 1Univariate analysis of clinical characteristics of pelvic masses following hysterectomy with or without simultaneous bilateral salpingectomyHys N(%)Hys + BS N(%)*P* valueTotal number of cases19814Age at hysterectomy (median\[IQR\], years)43 \[40,47\]42 \[36,44\]0.143 Group of age at hysterectomy  \< 45116 (58.6)11 (78.6)0.168  ≥4582 (41.4)3 (21.4)Etiology of hysterectomy Endometriosis/adenomyosis  No150 (75.8)4 (28.6)\< 0.0001  Yes48 (24.2)10 (71.4) Uterine leiomyoma  No64 (32.3)9 (64.3)0.020  Yes134 (67.7)5 (35.7) Postpartum massive hemorrhage  No195 (98.5)14 (100)1.0  Yes3 (1.5)0 (0) Cervical intraepithelial neoplasia  No186 (93.9)14 (100)1.0  Yes12 (6.1)0 (0) Endometrial intraepithelial neoplasia  No194 (98.0)14 (100)1.0  Yes4 (2.0)0 (0)Manifestation for medical consultation Physical examination findings  No96 (48.5)8 (57.1)0.531  Yes102 (51.5)6 (42.9) Abdominal distension and anorexia  No163 (82.3)13 (92.9)0.473  Yes35 (17.7)1 (7.1) Abnormal defecation  No190 (96.0)13 (92.9)0.466  Yes8 (4.0)1 (7.1) Abdominal pain  No151 (76.3)9 (64.3)0.339  Yes47 (23.7)5 (35.7) Micturition  No187 (94.4)14 (100)1.0  Yes11 (5.6)0 (0) Lower limb pain  No196 (99.0)14 (100)1.0  Yes2 (1.0)0 (0) Vaginal flow or bleeding  No194 (98.0)14 (100)1.0  Yes4 (2.0)0 (0)Total/Subtotal hysterectomy Total166 (83.8)14 (100)0.135 Subtotal32 (16.2)0 (0)Age of surgery for pelvic mass (median\[IQR\])50 \[47,56\]44.5\[41, 49\]\< 0.0001Age group \< 52114 (57.58)14 (100)0.001 ≥5284 (42.42)0 (0)The time interval from hysterectomy to the pelvic mass onset (median\[IQR\])5 \[2,10\]2 \[1,4\]\< 0.0001 Time group   \< 589 (44.95)11 (78.6)0.024   ≥ 5109 (55.05)3 (21.4)The time interval from hysterectomy to the pelvic benign mass onset (median\[IQR\])4.0\[2, 9.25\]\
(*n* = 134)1.5\[0.7,3.0\]\
(n = 8)\< 0.0001The time interval from hysterectomy to the pelvic malignant mass onset (median\[IQR\])7 \[3,10.75\]\
(*n* = 64)4.5 \[0.93, 8.25\]\
(*n* = 6)0.223*Abbreviations*: *BS* bilateral salpingectomy, *Hys* Hysterectomy, *IQR* interquartile rangeFig. 1**a** ROC curve of the age of hysterectomy; **b** ROC curve of the age of pelvic masses resected; **c** ROC curve of the time interval from hysterectomy to the pelvic mass onset

Results {#Sec8}
=======

Demographics data of study population {#Sec9}
-------------------------------------

Our study included 247 patients, of whom 80.16% (*n* = 198) received simple hysterectomy, 5.67% (*n* = 14) underwent hysterectomy with bilateral salpingectomy, 12.96% (*n* = 32) hysterectomy with unilateral salpingo-oophorectomy, 1.21% (n = 3) hysterectomy with bilateral salpingo-oophorectomy. In the group of simple hysterectomy, 166 cases (83.8%) performed total hysterectomy and 32 cases (16.2%) performed subtotal hysterectomy; while in the group of hysterectomy with simultaneous bilateral salpingectomy, all of the 14 cases were performed the procedure of total hysterectomy. The clinicopathological data of patients undergone simple hysterectomy or simultaneous bilateral salpingectomy was compared. Patients who undergone simple hysterectomy, 68.18% (*n* = 135) of the pelvic massed were benign, and the remaining 31.82% (*n* = 63) were malignant. In benign masses, ovarian origin accounted for 70.37%, oviduct origin 20.00%, encapsulated effusion 10.37%; in malignant masses, ovarian origin 76.19%, pelvic extraovarian malignancy 12.70%, peritoneal cancer 4.76%, gastrointestinal derived 4.76%. Patients who undergone hysterectomy with bilateral salpingectomy, 57.14% (*n* = 8) were benign and 42.86% (n = 6) were malignant. In benign masses, ovarian origin accounted for 37.50%, encapsulated effusion 50%, extraovarian benign mass 12.5%; in malignant group, ovarian origin 83.3%, and pelvic exogenous derived 16.7%.

Clinical characteristics between two groups {#Sec10}
-------------------------------------------

Univariate analysis showed that the age of surgery for pelvic mass in patients undergoing hysterectomy with simultaneous salpingectomy was significantly younger than those without salpingectomy \[median(IQR), 44.5 (41.0, 49.0) years vs 50.0 (47.0, 56.0), *P* \< 0.0001\]. Grouped by ROC curve, more patients below 52 years old with pelvic mass were found in salpingectomy group (100% vs 57.58%, *P* = 0.001). The time interval from hysterectomy to the pelvic mass onset was significantly shorter (median, 2 vs 5 years, *P* \< 0.0001) and more patients had the time interval less than 5 years in salpingectomy group. Further statistics were performed separately referring to the time interval from hysterectomy to the onset of benign and malignant pelvic masses. Results revealed that the time interval between benign pelvic masses and hysterectomy was shorter in salpingectomy group \[median(IQR), 1.5 (0.7,3.0) vs 4.0 (2, 9.25), *P* \< 0.0001\]. On the contrary, there was no difference between the two groups in the time interval between hysterectomy and malignant pelvic masses onset. In addition, the cause of hysterectomy being endometriosis or adenomyosis was significantly more common in the salpingectomy group (71.4% vs 24.2%, *P* \< 0.0001), while hysterectomy due to leiomyoma was less common (35.7% vs 67.7%, *P* = 0.020). There were no significant differences in age of hysterectomy and the main complaints of pelvic mass (Table [1](#Tab1){ref-type="table"}). Multivariate analysis showed that there was no significant difference in the time interval from pelvic mass onset to the hysterectomy between two groups. Thus, in the salpingectomy group, the etiology for hysterectomy being endometriosis or adenomyosis may be related to the earlier onset of pelvic masses (Table [2](#Tab2){ref-type="table"}).Table 2Multivariate analysis of clinical characteristics of pelvic mass after hysterectomy with or without bilateral salpingectomyParameterβS.E.*P* valueOR(95%CI)Intercept−2.4040.644\<.0001Endometriosis/adenomyosis1.5110.6400.0184.532 (1.293--15.880)Leiomyoma−0.7770.6510.2060.460 (0.138--1.535)Age of resection of pelvic mass−1.5230.8320.0670.218 (0.043--1.114)Time interval between hysterectomy and pelvic mass onset−0.2370.7410.7500.789 (0.185--3.373)Notes: In multivariate analysis, the equation is of significance when the *p* value of the whole test less than 0.0001

Pathology characteristics between two groups {#Sec11}
--------------------------------------------

The pathology characteristics were compared in patients undergone hysterectomy with and without bilateral salpingectomy. Univariate analysis showed that the incidence of pelvic encapsulated effusion was higher in the salpingectomy group (28.6% vs 7.1%, *P* = 0.021), while there was no significant difference between the two groups referring to other pathological types (Table [3](#Tab3){ref-type="table"}). However, when the main indications of hysterectomy (endometriosis/adenomyosis and leiomyoma) were included in analysis, multivariate analysis showed that there was no significant difference of the incidence of pelvic encapsulated effusion between the two groups (Table [4](#Tab4){ref-type="table"}). This may be explained by the previous history of endometriosis or adenomyosis in the salpingectomy group.Table 3Univariate analysis of pathological characteristics of pelvic mass after hysterectomy with or without simultaneous bilateral salpingectomyHys N(%)Hys + BS N(%)*P* valueTotal number of cases19814Malignant No135 (68.2)8 (57.1)0.391 Yes63 (31.8)6 (42.9) Ovarian serous carcinoma  0175 (88.4)11 (78.57)0.388  123 (11.6)3 (21.43) Ovarian mucous carcinoma  0190 (96.0)14 (100)1.0  18 (4.0)0 (0) Ovarian endometrioid carcinoma  0194 (98.0)14 (100)1.0  14 (2.0)0 (0) Ovarian clear cell carcinoma  0195 (98.5)13 (92.9)0.241  13 (1.5)1 (7.1) Ovarian sarcoma  0196 (99.0)13 (92.9)0.186  12 (1.0)1 (7.1) Ovarian undifferentiated carcinoma  0196 (99.0)14 (100)1.0  12 (1.0)0 (0) Ovarian primary PNET  0198 (100)14 (100)1.0  10 (0)0 (0) Other uncertain types of ovarian carcinoma  0192 (96.97)14 (100)1.0  16 (3.0)0 (0) Pelvic extraovarian carcinoma  0190 (96)13 (92.9)0.466  18 (4)1 (7.1) Peritoneal derived carcinoma  0195 (98.5)14 (100)1.0  13 (1.5)0 (0) Vaginal stump carcinoma  0197 (99.5)14 (100)1.0  11 (0.5)0 (0) Carcinoma in other sites  0195 (98.5)14 (100)1.0  13 (1.5)0 (0)Benign No63 (31.8)6 (42.9)0.391 Yes135 (68.2)8 (57.1) Cervical leiomyoma  0194 (98.0)14 (100)1.0  14 (2.0)0 (0) Cervical intraepithelial neoplasia  0197 (99.5)14 (100)1.0  11 (0.5)0 (0) Hydrosalpinx  0178 (89.9)14 (100)0.371  120 (10.0)0 (0) Mesenchymal cyst of oviduct  0191 (93.9)14 (100)1.0  17 (6.1)0 (0) Ovarian oviduct abscess  0196 (99.0)14 (100)1.0  12 (1.0)0 (0) Ovarian endometriosis  0168 (84.8)12 (85.7)1.0  130 (15.2)2 (14.3) Ovarian physiological cysts  0178 (89.9)14 (100)1.0  120 (10.1)0 (0) Ovarian serous cystadenoma  0184 (92.9)13 (92.8)1.0  114 (7.1)1 (7.2) Ovarian mucinous cystadenoma  0178 (89.9)14 (100)0.370  120 (10.1)0 (0) Ovarian fibroma  0194 (98.0)14 (100)1.0  14 (2.0)0 (0) Ovarian teratoma  0195 (98.5)14 (100)1.0  13 (1.5)0 (0) Ovarian epidermoid cyst  0196 (99.0)14 (100)1.0  12 (1.0)0 (0) Encapsulated effusion  0184 (92.9)10 (71.4)0.021  114 (7.1)4 (28.6) Intravascular leiomyomatosis  0196 (99.0)13 (92.9)0.186  12 (1.0)1 (7.1) Pelvic leiomyoma  0196 (99.0)14 (100)1.0  12 (1.0)0 (0) Others benign masses arising from extraovarian sites  0192 (97.0)14 (100)1.0  16 (3.0)0 (0)*Abbreviations*: *BS* bilateral salpingectomy, *Hys* Hysterectomy, *IQR* interquartile range, *PNET* primitive neuroectodermal tumorTable 4Multivariate analysis of pathological characteristics of pelvic mass after hysterectomy with or without bilateral salpingectomyParameterβS.E.*P*OR(95%CI)Intercept−3.2600.649\<.0001Encapsulated effusion0.9700.6970.1642.639 (0.673--10.351)Endometriosis/adenomyosis1.7290.6510.0085.637 (1.574--20.187)Leiomyoma−0.7130.6290.2570.490 (0.143--1.683)Notes: In multivariate analysis, the equation is of significance when the *p* value of the whole test less than 0.0001

Discussion {#Sec12}
==========

Hysterectomy is one of the most commonly used surgical methods for gynecological benign diseases. Patients always hope that they will not receive reoperation for gynecological diseases when hysterectomy was performed, which is not the case. The occurrence of pelvic masses after hysterectomy is one of the most common causes for reoperation. 39% of women who underwent hysterectomy for benign gynecologic indications received elective bilateral salpingo-oophorectomy to prevent ovarian cancer \[[@CR7]\]. Recent studies shown that prophylactic bilateral salpingectomy is helpful not only in preventing high-grade serous type ovarian cancer, but also in decreasing adnexal pathologies \[[@CR8]\]. Question was raised subsequently on whether or not the fallopian tubes are resected during hysterectomy relate to the nature and origin of the subsequent pelvic masses. However, there is no consensus on whether bilateral fallopian tubes should be resected with hysterectomy for benign diseases in premenopausal women.

Total of 247 patients were enrolled in this study. In simple hysterectomy group, the most common chief complaints for the onset of pelvic mass were found by physical examination, abdominal distension and anorexia. Most common chief complaints in hysterectomy with salpingectomy group were found by physical examination and abdominal pain. 20.20% benign masses were derived from oviduct, and no malignant masses were derived from oviduct for the former group. Neither benign nor malignant masses were derived from oviduct in the latter group.

It has been thought that the fallopian tube has little physiological function after completing fertility, and may have potential of inducing cancer. More and more evidences show that ovarian cancer, especially high-grade serous carcinoma, originates from the fallopian tube. Malignant transformation of the fallopian tube can lead not only to fallopian tubal carcinoma, but also lead to the occurrence of ovarian and peritoneal carcinoma \[[@CR2], [@CR3]\]. Bilateral salpingectomy can reduce the risk of ovarian carcinoma for women with BRCA1/2 gene mutations or general population \[[@CR9]--[@CR12]\].

In addition, the retained fallopian tubes have the risk of secondary benign lesions, such as hydrosalpinx, fallopian tube ovarian abscess, fallopian tube prolapse, mesenchymal cyst of oviduct, etc. \[[@CR13]\]. It has been reported that the risk of reoperation due to tubal diseases after hysterectomy without bilateral salpingectomy is twice as high as that with bilateral salpingectomy. Morse, et al. reported that women who underwent hysterectomy had 8% lifetime risk of reoperation for hydrosalpinx \[[@CR14]\]. Another retrospective study reported that patients without preventive salpingectomy had a higher incidence of adnexal benign tumors (26.9% vs 13.9%, *P* = 0.02) \[[@CR15]\]. The percentage of simple hysterectomy and hysterectomy with bilateral salpingectomy in our study is similar to those of Shiber Linda Dalal, et al. (80.16, and 5.67% respectively in the former one; 76, and 4% respectively in the latter one,) \[[@CR16]\]. Shiber, et al. revealed that 82% of pelvic masses following hysterectomy are benign, and 18% were malignant. 12.4% were derived from fallopian tubes, accounting for 6.7% of benign masses and 12.9% of malignant masses. Therefore, the authors suggest that simultaneous salpingectomy with hysterectomy may reduce the incidence of benign tumors derived from the fallopian tubes. In this study, 68.2% of the pelvic masses in the simple hysterectomy group were benign and 31.8% were malignant. Tubular masses accounted for 16.2% of the total pelvic masses and 21.5% of the benign masses, and there were no malignant tumors. In the simultaneous salpingectomy group, 57.1% of the pelvic masses were benign and 42.9% were malignant with none of the masses derived from fallopian tube. Therefore, the results of this study are in accordance to the results of Shiber that hysterectomy combined with simultaneous bilateral salpingectomy may reduce the incidence of fallopian tubes derived pelvic masses, which accounted for 12.4--16.2% of total pelvic masses and 6.7--21.5% of total benign pelvic masses.

Furthermore, we compared the clinicopathological data of patients who underwent hysterectomy with and without simultaneous bilateral salpingectomy in this study. After adjusting the factors of more patients with endometriosis or adenomyosis in salpingectomy group, we found that there was no statistical difference between two groups on the age of pelvic mass onset, time interval between twice operations, main complaints when pelvic mass was found, and proportion of benign and malignant tumors. We also found that salpingectomy lead to no difference on the malignant pelvic masses between two groups, but cause difference on the benign pelvic masses. On the one hand, there were fewer cases with salpingectomy in this study, which may affect the statistical results. On the other hand, the objects of this study were the patients who underwent reoperation due to pelvic mass after simple hysterectomy with and without simultaneous bilateral salpingectomy, and we did not enrolled all patients underwent hysterectomy. Therefore, result of this study cannot concluded that simultaneous salpingectomy cannot reduce the incidence of benign and malignant masses, and cannot make difference on the nature of the pelvic masses. The prospective study we are currently conducting may help explaining this issue.

Conclusion {#Sec13}
==========

In conclusion, the results of this study showed that 14.65% of the pelvic masses in the hysterectomy group originated from fallopian tubes, accounting for 21.48% of the benign masses, while the pelvic masses in the salpingectomy group had no tumors originating from fallopian tubes. Therefore, hysterectomy with simultaneous bilateral salpingectomy may reduce the recurrence of pelvic masses, especially benign pelvic masses. However, there were no significant differences in clinical features and pathological types between the two groups.
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